Published 4 hours ago • loading... • Updated 4 hours ago
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Sarepta Therapeutics (NASDAQ:SRPT) Stock
Summary by MarketBeat
1 Articles
1 Articles
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Sarepta Therapeutics (NASDAQ:SRPT) Stock
JPMorgan Chase & Co. increased their price objective on Sarepta Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Thursday.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last Updated100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium






